Enbrel and Ticlopidine Hydrochloride

• Generic Name: etanercept
• Dosage Forms: subcutaneous injection
• Other Brand Names: Enbrel, Enbrel Prefilled Syringe, Enbrel SureClick, Erelzi Prefilled Syringe, Erelzi Sensoready Pen, Enbrel Mini Prefilled Cartridge

Enbrel (etanercept) is a tumor necrosis factor (TNF) blocker. It works by decreasing TNF, a protein produced by the immune system to helps the body fight infections. In people with autoimmune disorders, the immune system produces too much TNF and mistakenly attacks healthy cells.

Enbrel is used to treat rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and to prevent joint damage caused by these conditions.

Enbrel is also used to treat polyarticular juvenile idiopathic arthritis in children who are at least 2 years old.

Enbrel is also used to treat plaque psoriasis in adults and children who are at least 4 years old.

• Generic Name: ticlopidine
• Dosage Forms: n.a.
• Other Brand Names: Ticlid

Used to reduce the risk of fatal or nonfatal thrombotic stroke in patients who have had either a previous completed thrombotic stroke or stroke precursors (e.g., TIA, transient monocular or partial blindness [amaurosis fugax], reversible ischemic neurologic deficit, minor stroke).

Because of potentially life-threatening adverse effects (see Boxed Warning), reserve for patients who are unable to tolerate or have hypersensitivity to aspirin or those who have failed to respond to aspirin therapy where indicated to prevent stroke.

The American College of Chest Physicians (ACCP) states that use of ticlopidine for secondary prevention of stroke has become severely limited because of the risk of serious adverse effects and the availability of safer antiplatelet agents.

Used as an adjunct to aspirin therapy to reduce the incidence of subacute stent thrombosis after PCI with successful coronary artery stent placement.

Ticlopidine for this use largely has been replaced by other antiplatelet agents. ACCP and other experts currently recommend dual-drug antiplatelet therapy with other P2Y12-receptor antagonists (e.g., clopidogrel, prasugrel, ticagrelor) and aspirin in patients undergoing PCI with stent placement.